Compare LCID & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | BHVN |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2022 |
| Metric | LCID | BHVN |
|---|---|---|
| Price | $5.55 | $16.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $15.71 | ★ $29.08 |
| AVG Volume (30 Days) | ★ 13.1M | 3.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,271,000.00 | N/A |
| Revenue This Year | $71.67 | N/A |
| Revenue Next Year | $89.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $7.48 |
| 52 Week High | $25.22 | $18.57 |
| Indicator | LCID | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 76.57 |
| Support Level | $4.47 | $8.54 |
| Resistance Level | $5.53 | $18.37 |
| Average True Range (ATR) | 0.37 | 0.99 |
| MACD | 0.07 | 0.42 |
| Stochastic Oscillator | 92.13 | 95.38 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.